2016
DOI: 10.21873/anticanres.11155
|View full text |Cite
|
Sign up to set email alerts
|

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Abstract: Abstract. 223 Prostate cancer (PCa) is the most common malignancy in men (1). In patients affected by advanced PCa, defined as hormonesensitive disease since the tumor still requires androgen for growth, androgen deprivation therapy (ADT), including luteinizing hormone-releasing hormone (LHRH) agonists, antagonists and anti-androgens, represents the first-line treatment. Unfortunately some cancer cells develop resistance to ADT, indicating the progression of the disease to metastatic castration-resistant pro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 57 publications
(94 reference statements)
0
7
0
Order By: Relevance
“…It is recommended to indicate the Radium-223 treatment especially in patients with less advanced prostate cancer, who are more likely to undergo the complete treatment and thus benefit more from it. However, the PSA, skeleton scintigraphy, or FDG PET/CT scan are not suitable methods for patient selection or Radium-223 monitoring, as small visceral or other metastases might not be found [4, 7]. Thus, a more precise selection is desirable for selecting suitable patients with mCRPC; a new 68Ge/68Ga generator should help.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…It is recommended to indicate the Radium-223 treatment especially in patients with less advanced prostate cancer, who are more likely to undergo the complete treatment and thus benefit more from it. However, the PSA, skeleton scintigraphy, or FDG PET/CT scan are not suitable methods for patient selection or Radium-223 monitoring, as small visceral or other metastases might not be found [4, 7]. Thus, a more precise selection is desirable for selecting suitable patients with mCRPC; a new 68Ge/68Ga generator should help.…”
Section: Resultsmentioning
confidence: 99%
“…The therapeutic options for their treatment are bisphosphonates, denosumab, beta-emitting radionuclide palliative therapy, external radiotherapy, surgery, and, last but not least, new specific radionuclide therapy with an alpha emitter, Radium-223 ( 223 Ra) or its dichloride, 223 RaCl 2 [32]. Radium-223 is an alpha emitter with a half-life of 11.4 days that is selectively targeted to bone metastases, and, as the only one of the therapeutic options, it has a positive effect on patient survival [4]. The combination of targeted Radium-223 accumulation in the bones, high energy, and short-range alpha particles allows to kill target tumor cells, as it causes deoxyribonucleic acid (DNA) double-strand breaks.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Since prostate cancer is the most common type of cancer in men, considerable research is performed in order to improve the outcomes of these patients, including preclinical studies and clinical investigations of new systemic treatments, surgical approaches and radiation techniques (8)(9)(10)(11)(12)(13). In contrast to metastatic spread to the bone, metastases to the brain are very rare.…”
Section: Discussionmentioning
confidence: 99%